Clinical Trial Detail

NCT ID NCT02057133
Title A Study of LY2835219 in Combination With Hormone Therapies for Breast Cancer That Has Spread
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements yes
Sponsors Eli Lilly and Company

Her2-receptor negative breast cancer


Abemaciclib + Letrozole

Abemaciclib + Exemestane

Everolimus + Exemestane + LY2835219

Abemaciclib + Anastrozole

Abemaciclib + Tamoxifen

Abemaciclib + Trastuzumab

Age Groups: adult

Additional content available in CKB BOOST